Bottom line
SHISX vs FHLC: the short answer
SHISX (Blackrock Health Sciences Opportunities Portfolio) and FHLC (Fidelity MSCI Health Care Index ETF) are both mutual funds.
But FHLC is far broader, holding 337 positions to 155 for SHISX, so beyond the top names it adds exposure SHISX doesn't have.
FHLC is cheaper at 0.084% vs 1.16% — a difference of $108 a year per $10,000 invested.
Over five years, FHLC returned +7.2% a year vs +5.5% for SHISX (reporting dates differ).
Updated Nov 19, 2026
SHISX vs FHLC side by side
| SHISX | FHLC | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | BlackRock | Fidelity |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 1.16% | 0.084% |
| Annual cost per $10k | $116 | $8.4 |
| 10-yr cost on $10k (prospectus) | $1,409 | $108 |
| Max front load | — | None |
| 12b-1 fee | 0.25% | 0% |
| 1-yr return | +15.9% | +2.6% |
| 5-yr return (annualized) | +5.5% | +7.2% |
| 10-yr return (annualized) | +9.5% | +8.8% |
| Best quarter | +17.5% | +16.4% |
| Worst quarter | −11.5% | −13.1% |
| Net assets (fund) | $5.9B | $3.3B |
| Number of holdings | 155 | 337 |
| Portfolio turnover | 49% | 3% |
| Returns as of | Dec 31, 2025 | Nov 30, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | SHISX | FHLC | Difference |
|---|---|---|---|
| 2024 | +3.8% | +2.6% | +1.2% |
| 2023 | +3.5% | +2.5% | +1.0% |
| 2022 | −6.0% | −5.5% | −0.5% |
| 2021 | +11.7% | +20.4% | −8.6% |
| 2020 | +19.4% | +18.1% | +1.3% |
| 2019 | +25.3% | +21.9% | +3.3% |
| 2018 | +8.0% | +5.5% | +2.4% |
| 2017 | +24.8% | +23.3% | +1.5% |
| 2016 | −6.1% | −3.3% | −2.7% |
| 2015 | +11.0% | +7.0% | +4.0% |
Source: Fund prospectus bar charts
Holdings overlap
17 of SHISX's top 25 holdings also appear in FHLC's top 25.
| Holding | SHISX | FHLC |
|---|---|---|
| Eli Lilly & Company | 12.29% | 13.35% |
| Johnson & Johnson | 8.77% | 8.93% |
| Unitedhealth Group Inc | 6.10% | 5.44% |
| Merck & Company Inc | 4.94% | 4.66% |
| Gilead Sciences Inc | 4.19% | 2.34% |
| Abbvie Inc | 3.94% | 6.42% |
| Amgen Inc | 3.37% | 3.00% |
| Thermo Fisher Scientific Inc | 3.02% | 3.09% |
| Vertex Pharmaceuticals Inc | 2.74% | 1.76% |
| Pfizer Inc | 2.61% | 2.06% |
| Danaher Corp | 2.00% | 1.80% |
| Abbott Laboratories | 1.97% | 2.66% |
| Intuitive Surgical Inc | 1.95% | 1.82% |
| Boston Scientific Corp | 1.59% | 1.00% |
| Elevance Health Inc | 1.56% | 1.19% |
Source: SEC Form N-PORT
SHISX top 10
- Eli Lilly & Company — 12.29%
- Johnson & Johnson — 8.77%
- Unitedhealth Group Inc — 6.10%
- Merck & Company Inc — 4.94%
- Gilead Sciences Inc — 4.19%
- Abbvie Inc — 3.94%
- Amgen Inc — 3.37%
- Thermo Fisher Scientific Inc — 3.02%
- Vertex Pharmaceuticals Inc — 2.74%
- Pfizer Inc — 2.61%
FHLC top 10
- Eli Lilly & Co — 13.35%
- Johnson & Johnson — 8.93%
- AbbVie Inc — 6.42%
- UnitedHealth Group Inc — 5.44%
- Merck & Co Inc — 4.66%
- Thermo Fisher Scientific Inc — 3.09%
- Amgen Inc — 3.00%
- Abbott Laboratories — 2.66%
- Gilead Sciences Inc — 2.34%
- Pfizer Inc — 2.06%
FAQ
What is the difference between SHISX and FHLC?
Which is cheaper, SHISX or FHLC?
Should I own both SHISX and FHLC?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.